Atrial Fibrillation and Heart Failure: Update 2015 by Thihalolipavan, Sudarone & Morin, Daniel P.
  	

Atrial Fibrillation and Heart Failure: Update 2015
Sudarone Thihalolipavan, Daniel P. Morin
PII: S0033-0620(15)00053-5
DOI: doi: 10.1016/j.pcad.2015.07.004
Reference: YPCAD 667
To appear in: Progress in Cardiovascular Diseases
Please cite this article as: Thihalolipavan Sudarone, Morin Daniel P., Atrial Fibrilla-
tion and Heart Failure: Update 2015, Progress in Cardiovascular Diseases (2015), doi:
10.1016/j.pcad.2015.07.004
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
  
 
Atrial Fibrillation and Heart Failure: Update 2015 
 
 
Sudarone Thihalolipavan MD
1 
Daniel P. Morin, MD MPH FHRS FACC
1,2 
1
Ochsner Medical Center, New Orleans LA 
2
Ochsner Clinical School, Queensland University School of Medicine, New Orleans LA 
 
 
 
Corresponding Author: 
 
Daniel P. Morin MD MPH FHRS FACC 
Ochsner Medical Center, 1514 Jefferson Highway, New Orleans, LA 70121. 
Voice: 504-842-5059 
Fax: 504-842-4131 
Email: dmorin@ochsner.org 
 
Dr. Thihalolipavan has no disclosures. 
 
Dr. Morin has research grants from Boston Scientific and Medtronic, and has received 
honoraria from Biotronik, Boeringer-Ingelheim, Boston Scientific, CardioNet, 
Medtronic, St. Jude Medical, and Zoll. 
 
Key Words: Atrial fibrillation, heart failure, anti-arrhythmia drugs, catheter ablation, 
anticoagulation 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Abstract:  
Heart failure (HF) and atrial fibrillation (AF) commonly coexist, 
adversely affect mortality, and impose a significant burden on 
healthcare resources. The presence of AF and HF portends a poor 
prognosis as well as an increased thromboembolic risk. In patients 
whose AF is symptomatic, rhythm restoration with either 
antiarrhythmic drugs or procedural therapies (e.g., pulmonary vein 
isolation, either catheter-based or surgical) should be considered for 
symptom improvement, though a mortality benefit has yet to be 
demonstrated. Emerging evidence suggests that non-pharmacological 
treatment for AF (including catheter based ablation, hybrid surgical 
techniques, and atrioventricular node ablation with biventricular 
pacing) may be of value in improving HF patients’ quality of life.  
Abbreviations: 
6MWT-6-minute walk test 
AADs-Anti-arrhythmia drugs 
ACEIs-Angiotensin converting enzyme inhibitors 
AF-Atrial fibrillation 
ARBs-Angiotensin receptor blockers 
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BB-Beta blockade 
BNP-Brain natriuretic peptide 
CA-Catheter ablation 
CHD-Coronary heart disease 
CRT-Cardiac resynchronization therapy 
CV-Cardiovascular 
CVA-Cerebral vascular accident 
HF-Heart failure 
HFpEF-Heart failure preserved ejection fraction 
HfrEF-Heart failure reduced ejection fraction 
LV-Left ventricular 
LVEF-Left ventricular ejection fraction 
NOACs-Novel oral anticoagulants 
NSR-Normal sinus rhythm 
NYHA-New York Heart Association 
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OACs-Oral anticoagulants 
PVI-Pulmonary vein isolation 
QoL-Quality of life 
STE-Systemic thromboembolism 
VKAs-Vitamin K antagonists 
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 Atrial fibrillation (AF) is the most common sustained arrhythmia 
among adults. [1] Heart failure (HF) and AF often coexist. Each condition 
can promote the other, with an associated increase in morbidity and 
mortality. Together, their incidence and prevalence is on the rise, 
presenting a growing clinical and economic burden [2]. In order to 
provide optimal care, clinicians should remain abreast of relevant 
literature, guideline recommendations, and available therapies for their 
patients. In this article we review the complex relationship between AF 
and HF, with a focus on recent advances in management as well as 
emerging evidence.  
 
 
Epidemiology of HF and AF 
  Both AF and HF are common clinical entities. HF alone is a 
significant and growing epidemic, affecting nearly 5.7 million American 
adults. [2] The prevalence of AF is increasing as the population ages, 
currently affecting over 2 million people in the United States. [1] 
Collectively, AF and HF carry significant morbidity and mortality, while 
imposing a substantial adverse impact on healthcare resources. Overall, 
the estimated national annual cost of caring for patients with AF is 
approximately $26 billion. [3] Likewise, HF hospital admissions account 
for over 6.5 million hospital days annually [4], and HF-related costs reach 
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an estimated $34.4 billion each year. This total includes the cost of 
health care services, medications, and lost productivity. [5]  
 AF and HF often coexist, and when they do, they confer increased 
risk for hospitalization, portend lengthier inpatient stays, and increase 
overall morbidity and mortality. [6-10] Piccini et al. analyzed 27,829 HF 
admissions at 281 hospitals between 2006 and 2008, and found that 
pre-existing AF was associated with greater 3-year risks of all-cause 
mortality (HR 1.14; 99% confidence interval [CI]: 1.08-1.20), all-cause 
readmission (HR: 1.09; 99% CI: 1.05-1.14), HF readmission (HR: 1.15; 
99% CI: 1.08-1.21), and readmission for stroke (HR: 1.20; 99% CI: 1.01-
1.41), compared with no AF. There also was a greater hazard of mortality 
at one year among patients with new-onset AF (HR: 1.12; 99% CI 1.01-
1.24) compared with no AF. [11] 
 
Pathophysiology of AF and HF 
AF and HF share several common risk factors and commonly occur 
together. [6-10,12-19]. The complex underlying mechanisms that lead to 
the development of AF in HF patients, and the converse relationship, have 
been partially described.  In patients with HF, there is evidence to support 
structural, neurohormonal, and electrical atrial remodeling – each of 
which may encourage the development of AF. [20-26] The development 
of AF in HF appears to be a multifactorial process, including early atrial 
enlargement, conduction heterogeneity from intra-atrial fibrosis, ion 
channel dysregulation, and autonomic remodeling (see Figure1). [27-30] 
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This causative relationship also works in the opposite direction: AF can 
induce electrical and hemodynamic deterioration and can cause 
tachycardia-mediated cardiomyopathy, resulting in HF. [31-33] Through 
induction of a rapid ventricular response or altered diastolic ventricular 
function, AF also can cause HF symptoms even in patients with intact LV 
systolic function. 
 
Anticoagulation  
 The presence of AF in patients with HF increases the risk of stroke 
and systemic thromboembolism (STE) when compared to those without 
AF. [34] Likewise, AF can lead to left ventricular (LV) dysfunction, which in 
turn can compound the stroke risk. The risk of STE when HF is combined 
with AF is well described, and the clinical burden of STE events with 
regard to morbidity and mortality is substantial. [35] As described initially 
by the Framingham Heart Study investigators, the presence of HF carries 
a fourfold risk of STE events per year. [36] Other studies, including the 
Stroke Prevention in Atrial Fibrillation study (SPAF), have also 
demonstrated that LV dysfunction is a particularly significant 
independent risk factor for cerebral vascular accident (CVA.) [37-43]  
Risk stratification schemes such as the CHADS2 and CHA2DS2-VASc 
scores divide patients into low, intermediate, and high-risk groups and 
are invaluable in assessing the need for anticoagulation. [44-47] Recently 
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the American Heart Association/American College of Cardiology/Heart 
Rhythm Society AF guidelines have promoted the utility of the CHA2DS2-
VASc over the CHADS2 score to identify patients who are at truly low risk 
for STE events. [48] Additionally, the CHA2DS2-VASc score takes into 
consideration risk factors that were not previously accounted for (i.e., 
female sex, age 65-75 years, vascular disease). [49] Patients at high 
stroke risk (i.e., CHA2DS2-VASc ≥2) clearly benefit from anticoagulation 
with oral anticoagulants (OACs; either vitamin K antagonists [VKAs] or the 
novel oral anticoagulants [NOACs; see below]). Patients at intermediate 
risk (CHA2DS2-VASc score of 1) are eligible for either aspirin alone or OAC 
therapy. [48] In AF patients with HF as their only risk factor, however, 
there is some evidence to suggest that therapy with OAC may be superior 
to aspirin alone (see below).  
Recent data from smaller series of patients suggest that among 
intermediate-risk patients with AF, VKAs may be superior to antiplatelet 
agents alone for CVA protection, without a significant difference in major 
bleeding. [50] In a study of such patients, Gorin et al. reported a lower 
rate of CVA and mortality with VKA (RR=0.42, 95% CI 0.29-0.60, 
p<0.0001). [51] Overall, VKAs are to be superior to antiplatelet regimens 
in intermediate-risk patients, but this has not been specifically described 
in patients with HF. [52] 
Importantly, the independent risk of stroke in patients with HF 
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complicating AF may be underestimated by commonly used risk 
stratification schemes. Specifically, similarly scored individual risk factors 
for STE events in AF do not imply exactly equivalent actual additional risk. 
[37-40, 53,54] Notably, in the Framingham Heart Study, HF carried a 
fourfold risk of STE events per year, whereas hypertension and coronary 
heart disease (CHD) implied only three times and twice the risk, 
respectively. [36] Thus, many experienced clinicians elect to 
anticoagulate patients with HF as their only CHA2DS2-VASc risk factor, 
using either VKA or a NOAC, if the bleeding risk is low. When making this 
decision, the HAS-BLED score can be utilized to assess the bleeding risk 
of anticoagulation. [55]  
Clinical trials assessing the risk of STE events in AF have used 
various definitions for the diagnosis of HF. To date, clinical risk scores do 
not differentiate between clinical HF with preserved ejection fraction 
(HFpEF) and LV systolic dysfunction with or without HF symptoms. [44-
46,48] Attempts have been made to correlate risk with the level of 
systolic dysfunction, but the results are mixed. [56-58] However, these 
data are confounded by inequalities in comorbid clinical factors that sway 
the results. From the best available evidence, it appears that there is no 
difference between HFpEF and LV systolic dysfunction in terms of 
CVA/STE risk. [57] Given the available evidence, we advise that the 
presence of clinical HF with evidence of either impaired LV systolic or 
diastolic function should imply to the clinician greater stroke risk than 
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when HF is absent, as has been suggested by Boos et al. [59]  
 The NOACs dabigatran, rivaroxaban, apixaban, and edoxaban, have 
recently become FDA approved for stroke prevention in nonvalvular AF, 
and are gaining widespread use. Data from the RE-LY and ARISTOTLE 
trials (examining dabigatran and apixaban, respectively) showed 
antithrombotic superiority, while ROCKET AF and ENGAGE AF-TIMI 48 
(examining rivaroxaban and edoxaban, respectively) demonstrated 
noninferiority when compared to VKA. [60-63] Conveniently for the 
present review, these trials featured relatively large proportions of HF 
patients (32%-63%) with only small interstudy discrepancies in their 
criteria for the diagnosis of HF. Specifically, these trials included patients 
with current clinical HF, or ≥New York Heart Association (NYHA) II 
symptoms within 6 months of the enrollment, in their HF cohorts. 
However, LV ejection fraction (LVEF) <40% qualified for systolic 
dysfunction in RE-LY and ARISTOTLE, while patients in ROCKET AF 
required LVEF<35% for the diagnosis of HF. Of note, HF was not 
specifically defined in ENGAGE AF-TIMI 48.  
Detailed subgroup analysis in the major NOAC trials showed similar 
benefit in the subgroups with HF with reduced LVEF (HfrEF) and HFpEF to 
what was found in the total study population. [60-62] For example, an 
analysis from ARISTOTLE compared patients with LV systolic dysfunction 
(LVEF <40%) to patients with HFpEF (LVEF >40%), and found no difference 
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in the risk of STE events in warfarin-treated patients, nor in subsequent 
reduction of risk with apixiban. [64]                   
 The advantages of the NOACs over VKA include the convenience of 
a fixed therapeutic dose without obligatory monitoring. Of note, however, 
HF patients often demonstrate variable renal function, which may 
influence circulating levels of prescribed NOACs, although apixaban 
undergoes only ~30 % renal metabolism and is approved even in severe 
renal failure and dialysis patients. In such patients, however, caution with 
the use of many NOACs seems prudent. Potential drawbacks of NOACs 
are their relatively increased cost compared with VKA, and the present 
lack of a commercially available reversal agent. Warfarin remains an 
acceptable therapy for many patients, and may be the only option when 
NOACs are cost prohibitive.  
For most patients, VKA is most effective when the INR is 
maintained between 2 and 3. Based on evidence from the ACTIVE A and 
W Trials, the INR must be maintained in this therapeutic range >65% of 
the time to achieve the therapeutic benefit of warfarin for prevention of 
embolization. [52, 65-66] Low scores on the novel risk tool SAMe-TT2R2 
have been shown by Lip et al. to identify patients who will likely have a 
high time in therapeutic range, and hence may derive the most benefit 
from VKA. [67] Conversely, high SAMe-TT2R2 scores predict low TTR, 
perhaps favoring treatment with a NOAC. 
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 Lastly, increased bleeding risk with concomitant anti-platelet 
agents and OACs should be taken into consideration in patients with AF. 
In a retrospective analysis of 37,464 patients with HF and vascular 
disease, the addition of a single antiplatelet agent to VKA therapy was not 
found to enhance benefit in either thromboembolic (HR 0.91; 95% CI 
0.73-1.12) or CHD risk (HR 1.11; 95% CI 0.96-1.28), but increased the 
frequency of bleeding (HR 1.31; 95% CI 1.09-1.57). [68] 
 
Rate control or rhythm control 
 Thus far, randomized clinical trials have yet to demonstrate any 
mortality benefit from pharmacological rhythm control in patients with 
HF. Data from two large trials, including one exclusively examining HF 
patients, did not support benefit of a rhythm control strategy with regard 
to overall mortality and stroke risk. [69, 70] This was an unexpected 
finding, given data from registry populations and study subsets 
suggesting adverse outcomes with HF and prevalent AF. [6-9, 12, 16] 
Critics have argued that imperfect effectiveness of normal sinus rhythm 
(NSR) maintenance and adverse effects of current pharmacological 
therapy potentially limited benefit of rhythm control in these studies. [71] 
The Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) trial was the largest randomized trial to compare 
the rate-control and rhythm-control strategies. AFFIRM demonstrated 
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similar all-cause mortality at five years (24 vs. 21%, P=0.08).   
Supplementary analysis suggested that there was a gross mortality 
benefit to successful maintenance of NSR, but that effect was neutralized 
by an increase in mortality associated with antiarrhythmic drug (AAD) 
use. [72] Only 23% of patients in AFFIRM had clinical HF, so extrapolation 
of these findings to the HF population must be made with caution. [69] 
The AF in Congestive Heart Failure (AF-CHF) trial was the most 
recent investigation comparing these two treatment strategies in HF 
patients specifically. The AF-CHF investigators randomized 1376 patients 
with systolic dysfunction and AF to rhythm control vs. rate control. There 
was no identified difference in overall survival, cardiovascular (CV) death, 
worsened HF, or stroke. [70] Unlike in AFFIRM, a post hoc analysis of AF-
CHF failed to demonstrate any benefit to successful NSR maintenance, 
and use of antiarrhythmic agents was still associated with increased 
mortality. [73] The authors stressed that the mortality benefit of 
maintaining NSR is likely outweighed by the incomplete efficacy of, and 
adverse effects related to, current AADs. Arguably, the AAD-related 
increase in mortality in older trials could be accounted for by frequent 
use of Class I AADs, which may themselves increase mortality in some 
populations. However, patients in the AF-CHF trial instead received either 
amiodarone or dofetilide (Class III AADs) and still failed to demonstrate 
benefit. [70,74-76] Whether Class III drug toxicity was partly responsible 
for this finding is unclear at this time. 
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 Given these data, AADs are primarily appropriate for symptom 
amelioration and improvement in quality of life (QoL), rather than for 
extension of life.  Not surprisingly, many patients with HF have significant 
symptoms while in AF as compared to when they are in NSR. Because 
patients with HF may be more dependent on the left atrium’s contribution 
to LV filling, they may benefit more from restoration of NSR than would 
their counterparts without HF. While large randomized studies such as 
AFFRIM and AF-CHF examined the endpoint of mortality (and failed to 
show a benefit), symptom relief was not studied specifically. [69,70] In 
contrast, the Randomized Controlled Study of Rate Versus Rhythm 
Control in Patients with Chronic Atrial Fibrillation and Heart Failure 
(CAFÉ-II) demonstrated in patients assigned to rhythm control not only 
improved QoL (p = 0.019), but also improved LV function (p = 0.014) and 
lower NT-pro Brain Natriuretic Peptide (BNP) levels (p = 0.05) at one year. 
[77] However, similar NYHA class and 6-minute walk test (6MWT) 
distance were observed whether a rate-control or rhythm-control 
strategy was pursued (p=NS for both). [77] The management strategy of 
NSR restoration with AADs is appropriate in HF patients with symptomatic 
AF.  
Of the available AADs, only amiodarone and dofetilide are 
recommended in patients with LV dysfunction and/or clinical HF (see 
Table 1). [48] Amiodarone is the most effective AAD, but its potency is at 
best 60% at one year and its use carries a non-negligible risk of adverse 
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effects. [78,79] Dofetilide therapy is less effective, and its initiation 
requires a three-day hospitalization due to its potential to prolong the 
QT interval, which can lead to torsades de pointes in 0.8-3.3% of 
patients. [48, 80-81] Because dronedarone was associated with increased 
mortality in randomized hospitalized patients with advanced HF (NYHA 
III-IV), its trial in the HF population was terminated early. [82] Currently, 
dronedarone is not recommended for patients with advanced HF nor in 
patients with recent decompensated HF. [48]  
Newer AADs including vernakalant, budiodarone, and adjuvant 
ranolazine (which was used with dronedarone in the HARMONY trial) are 
also being investigated, and may meet the promise of efficacy with 
improved safety. However, current trials examining these agents do not 
include patients with significant LV dysfunction. [83-86]  
 
Upstream Therapy for AF Prevention in HF 
 Interest is burgeoning in primary prevention of AF in patients with 
LV dysfunction. Evidence for the utility of upstream (non-antiarrhythmic) 
therapy has emerged from observations in large clinical trials and 
experimental data. [87-89] These therapies treat the underlying 
condition while targeting substrates, such as atrial remodeling and 
fibrosis, that have been implicated in the development of AF. [27] 
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 Therapy with angiotensin converting enzyme inhibitors (ACEi) 
and/or angiotensin receptor blockers (ARB) has been shown to prevent 
cardiac remodeling and fibrosis, and these drugs appear to be a 
reasonable and safe additive nonantiarrhythmic intervention. 
Retrospective analyses of large clinical trials have identified ACEi use 
among HF patients as an effective therapy in reducing the incidence of 
AF. [88,89] For example, a substudy of the Studies of Left Ventricular 
Dysfunction (SOLVD) trial demonstrated lower AF occurrence in patients 
treated with enalapril over 2.9 years (5.4% vs. 24% with placebo; 
P<0.0001).[89] As seen in the Valsartan Heart Failure Trial (Val-HeFT) 
and the Candesartan in Heart Failure: Assessment of Reduction in 
Mortality and Morbidity (CHARM) study, ARBs also showed some benefit, 
but with more modest results. [90,91] In CHARM, for example, in which 
AF was a prespecified secondary endpoint, among 6379 patients with 
symptomatic HF, new onset AF was lower in the group treated with 
candesartan (5.6% vs. 6.7%; P=0.048). Thus, the 2014 AHA/ACC/HRS AF 
guidelines support ACEis or ARBs as reasonable therapy for primary 
prevention of AF in patients with HFrEF. [48] Interestingly, the efficacy of 
ARBs to prevent AF so far may be limited to patients with structural heart 
disease. Specifically, the Angiotensin II-Antagonist in Paroxysmal Atrial 
Fibrillation (ANTIPAF) trial randomized 430 patients without structural 
heart disease to either placebo or olmesartan, and found no difference 
(P=0.77) in AF burden during a 12-month follow-up period. [92]  
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 Beta blockade (BB) may not be as useful for the treatment of HF in 
patients with AF as it is in patients in NSR. At present, major guidelines 
do recommend BB in patients with HF and AF (Class I, level of evidence 
A). [48] Additionally, robust trial data show convincingly that BB reduces 
morbidity and mortality among HF patients in general. [93-96] Although 
not specifically studied in the HF population, there was no previous signal 
of harm. However, two large meta-analyses recently suggested that the 
use of BB as standard therapy in concomitant AF and HF should be 
revisited. [97,98] Investigators from the β-blocker in Heart Failure 
Collaborative Group assessed trials involving a total of 18,254 patients 
(3,066 [17%] with AF), and found that BB led to a reduction in all-cause 
mortality in patients with NSR (HR 0.73; 95% CI 0.67–0.80; p<0.001), but 
not in patients with AF (HR 0.97; CI 0.83–1.14; p=0.73), when compared 
to placebo. [97] In a separate meta-analysis, Rienstra  et al. had similar 
findings when examining trials totaling 8,680 patients with HF, of whom 
1,677 had AF. In this meta-analysis, again BB showed significant 
reduction in mortality in patients in NSR (OR: 0.63; 95% CI 0.54-0.73) but 
not in patients with AF (OR 0.86; CI 0.66-1.13). [98] Likewise, in both 
analyses, BB was not associated with a reduction in HF hospitalizations 
among patients in AF. Interestingly, BB was associated with a 33% 
reduction in new onset AF (4% vs 6%, OR 0.67 [0.57-0.79]). [97] 
Additionally, a meta-analysis of seven large RCTs of BB found similar 
results: a reduced risk of AF (OR 0.73) among 11,952 patients with HF.  
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[99] In sum, therefore, the evidence suggests that BB can reduce the 
incidence of AF in HF patients, but they do not seem to be as effective in 
preventing major adverse CV outcomes in AF patients with chronic HFrEF. 
The authors have cited several plausible explanations for this differential 
effect of BB, including adverse impact of slow heart rate during AF, or 
that AF is simply a marker of a worse clinical condition in which 
improvement is more difficult to achieve.  [97] 
 In patients with LVEF <35% and mild symptoms (NYHA II), the 
addition of the aldosterone blocker eplerenone to an optimal HF regimen 
demonstrated further reduction in new onset AF (HR 0.58, P=0.034). 
[100] The utility of upstream therapy for the primary prevention of AF in 
patients with known LV dysfunction should not be disregarded. While 
further randomized data are needed, the experience with these now 
conventional HF therapies supports their role in primary prevention of AF 
in HF.  
 
Catheter-Based AF Ablation in HF 
 In part due to the risks of AADs and its incomplete success in 
maintaining NSR, catheter-based ablation  (CA) has emerged as a 
formidable therapeutic option in the management of AF. [101] Current 
data regarding CA support its safety, efficacy, and utility in alleviating 
symptoms and improving QoL. [102,103] However, whether CA reduces 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
all-cause mortality, stroke, and HF is still under investigation. [104]  
 Most patients included in CA trials are relatively young, with little 
co-morbidity, and normal to mildly reduced LVEF. [102] However, in two 
randomized controlled trials comparing CA to AAD, encouraging evidence 
showed clinical equivalence between these two therapies. These findings 
further support the recent American Heart Association/American College 
of Cardiology/Heart Rhythm Society Class IIa recommendation in favor of 
CA as first line therapy in patients with symptomatic paroxysmal AF, after 
considering the risks and benefits of AADs versus CA. Likewise, CA-
based pulmonary vein isolation (PVI) is a Class I indication for CA when 
AF is refractory to therapy with at least one AAD. [48, 105-106] It should 
be noted that the latest CA guidelines do not distinguish patients with LV 
dysfunction from those without, but they do mention that recurrence 
rates and complication rates may be higher in the cardiomyopathic 
population. [48] 
 In nonrandomized studies of HF patients with AF, catheter-based 
PVI has demonstrated benefit, including improvements in CV function, 
exercise capacity, and QoL. [107-110] Reports vary from 73% to 87% 
success in maintaining NSR among HF patients at one year post-
procedure. Additionally, post-PVI improvements in LV function have been 
noted. For example, in ARC-HF (A Randomized Trial to Assess Catheter 
Ablation Versus Rate Control in the Management of Persistent Atrial 
Fibrillation in Chronic Heart Failure), an open-label, blinded-endpoint 
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trial, 52 symptomatic AF patients with LVEF<35% were followed for 12 
months after randomization to PVI vs. rate control. These investigators 
reported a success rate of 88% for maintaining NSR at one year in 
patients who underwent PVI. Following PVI, objective exercise 
performance improved, including peak oxygen consumption (+3.07 
ml/kg/min, p=0.02). In addition, Minnesota symptom scores were 
improved, BNP was lower, and trends toward improved 6MWT (p=0.10) 
and LVEF (p=0.055) were demonstrated. [111] More recently, a single-
center randomized trial, CAMTAF (Catheter Ablation Versus Medical 
Treatment of AF in Heart Failure), found that CA was effective in restoring 
NSR (81%) in selected patients with persistent AF and HF.  Baseline LVEF 
was 32±8% in the CA group and 34±12% in the medical group. 
Investigators reported improved LV function at 6 months in the ablation 
group compared with the rate control group (40±12% vs. 31±13%; 
P=0.015), as well as improved functional capacity (22±6 vs. 18±6 mL/kg 
per minute; P=0.014) and HF symptom scale score (24±22 vs. 47±22; 
P=0.001). [112] 
 Clearly, CA is rapidly evolving at present, and improvements in the 
efficacy and safety of this procedure occur frequently. [113] Numerous 
studies have demonstrated the superiority of CA over medical therapy in 
maintaining NSR in structurally normal hearts. The initial experience 
suggests that these advantages may also extend to patients with HF – 
however at this time the number of randomized studies remains small. 
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Unquestionably, additional prospective data describing CA-related 
mortality and morbidity in patients with LV dysfunction are needed. 
Ongoing clinical trials such as the Canadian RAFT AF (A Randomized 
Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control 
Trial in Patients With Heart Failure and High Burden Atrial Fibrillation) and 
the international CASTLE-AF (Catheter Ablation Versus Standard 
Conventional Treatment in Patients With Left Ventricular Dysfunction and 
Atrial Fibrillation) trials may help to fill this void. [104,114] At the present 
time, CA appears to be technically feasible in symptomatic patients with 
HF, without a significantly higher procedural complication rate than in 
patients without HF. [113] Catheter-based PVI may also improve LV 
performance, reduce symptoms, and improve QoL.  
 
Atrioventricular Node (AVN) Ablation  and Pacing for Cardiac Resynchronization 
Therapy (CRT) 
Recently, CRT with subsequent radiofrequency ablation of the AVN 
has been shown to be effective in AF patients with a rapid ventricular 
response who are refractory to medical therapy (Class IIa 
recommendation). [115] Likewise, patients with persistent/permanent AF, 
an implanted CRT device, and suboptimal biventricular pacing also may 
benefit from AVN ablation. [116] By eliminating rapid intrinsic ventricular 
activation, AVN ablation in these HF patients may optimize synchronized 
biventricular activation. [117] 
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A recent meta-analysis, including data from 450 patients with 
concomitant HF and AF in three non-randomized trials, concluded that 
AVN ablation was associated with a reduction in all-cause mortality (RR 
0.42, p<0.001) and CV mortality (RR 0.44, p=0.008). [118] However, long 
term outcome data suggest that for several outcome measures, PVI 
outperforms AV node ablation and pacing.[110] For instance, the 
Pulmonary Vein Isolation for AF in Patients with Heart Failure (PABA-CHF) 
trial showed that those randomized to PVI had a significantly higher mean 
LVEF (35% vs. 28%), better performance on the 6MWT (340 vs. 297 m), 
and a superior QoL score. [119] Additionally, another trial in elderly 
patients showed a higher incidence of new HF at 5 years in the ablate-
and-pace group when compared to those who underwent AF ablation 
(53% vs. 24%). [120]  
 
Surgical and Hybrid Therapy  
 Surgical therapy of AF (e.g., via the Cox Maze procedure) can result 
in high rates of freedom from arrhythmia (up to 93%) over an 8.5-year 
follow up period, with an operative mortality of 3%. [121, 122] Surgical 
PVI techniques using either radiofrequency ablation or cryoablation are 
less complicated than the full Maze procedure, and do not require an 
atriotomy nor additional time on cardiopulmonary bypass. [122] 
Procedural success with surgical PVI has been generally favorable but 
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variable (50-91%). [122] Current recommendations suggest standalone 
AF surgery in symptomatic AF patients who have failed medical 
management and prefer a surgical approach, or have failed one or more 
attempts at CA, or are not candidates for CA. [123] 
  A novel minimally invasive, hybrid epicardial and endocardial CA 
approach called the “Convergent” procedure shows promise. [124] The 
procedure circumvents sternal and/or thoracic incision by utilizing a sub-
diaphragmatic endoscopic access to deliver epicardial CA lesions, and 
also uses simultaneous endocardial C . While safety and efficacy of this 
procedure have been established in nonrandomized trials, there is a 
paucity of experience in HF patients. [124,125]  
 
Conclusion: 
Concomitant AF and HF consistently demonstrate a poor prognosis, 
increase hospitalization, and adversely affect mortality. While shared risk 
factors account for much of their frequent co-existence, HF can also 
cause AF, and vice versa. Certainly, HF begets AF via a complex interplay 
of atrial stretch, fibrosis, autonomic dysregulation and inflammation. 
Restoration of NSR with AADs can be effective in alleviating symptoms, 
but has failed to show a mortality benefit over rate control. Nevertheless, 
current AADs continue to have limited efficacy in NSR promotion, and CA 
has been shown to be superior to AADs in maintaining NSR. While 
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improvements in QoL and morbidity have been reported in HF patients, 
limited data exist regarding this population.  Ongoing randomized 
multicenter studies examining mortality as well as HF outcomes with CA 
are currently underway. These data will hopefully clarify the utility of CA 
in patients with concomitant AF and HF.  At the present time, the 
existence of symptoms when the patient is in AF is the primary indication 
for rhythm restoration over rate control. Lastly, novel risk 
characterization schemes and OACs are now accessible, and knowledge 
of their utility and limitations are necessary to optimize the care for 
patients with both AF and HF.  
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Figure 1: The interrelated pathophysiology of AF and HF 
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Table 1: Antiarrhythmic Agents for Atrial Fibrillation in Heart Failure 
        Agent        Dosing   Adverse Effects             Interactions 
Amiodarone 100−200 mg. 
PO load 1.2 g-
1.8g/day until 
10 g total. 
•Hypo- or 
hyperthyroidism, 
retinal deposits, 
pulmonary 
fibrosis, 
hepatotoxicity 
•Numerous; CYPs to cause 
drug interaction; Inhibits 
P-glycoprotein: ↑digoxin 
concentration 
Dofetilide 125–500 mcg 
BID, based on 
renal function 
•Prolonged QT 
interval, Torsades 
de Points (TDP), 
dizziness, 
diarrhea.  
 
•Primary renal elimination  
*Avoid other QT 
interval−prolonging drugs; 
verapamil, HCTZ, 
cimetidine, ketoconazole, 
trimethoprim, 
prochlorperazine, and 
megestrol are 
contraindicated 
Dronedarone 400 mg BID •QT prolongation, 
hepatotoxicity, 
abdominal pain, 
HF exacerbation, 
bradycardia 
               
*Do not use in 
advanced HF, or 
with recent 
hospitalization  
 
•CYP3A, P-glycoprotein 
interactions; 
↑concentrations of some 
statins, digoxin, 
dabigatran, other drugs 
* Modified with permission from the ACC/AHA/HRS 2014 guidelines Am Coll Cardiol. 
2014;64(21):2246-2280 
